Oncology Exchange Fall 2024

Arlington, TX | November 1-2, 2024

2025 GPOconnect Roadmap

Leveraging partners for new revenue streams and clinical quality programs

Maximizing Net Cost Recovery through Analytics

Navigating a PBM Audit

Payer Speed Dating: Insights from a selection of payers

Exploring the latest data on treatment options for patients with PD-L1 <1% metastatic NSCLC and resectable NSCLC

Introducing VYLOY (zolbetuximab-clzb): A New Treatment Option for Your Patients with Advanced* HER2-Negative G/GEJ Cancer (MAT-US-ZOL-2024-00419)

Cell Therapy in Myeloma—aSCT, Bispecifics and CAR-T: Where We’ve Been and Where We’re Going

Exploring Time Off Treatment with a BCL-2 Inhibitor: A review of VENCLEXTA-based Regimens for Patients with CLL/SLL

Recent Advances in Lung Cancer

Working Together to Advance Guideline-Recommended Care for Early-Stage NSCLC: Benefits of the Multidisciplinary Team

An Innovative First-Line Treatment Option in EGFR+ Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Priorities in Partnership – What to expect from the GPO in 2025

Implications of the Inflation Reduction Act: Provider & Pharma Perspectives

Cencora Leadership Executive Address

Conversations with Kathy: Discussions on current topics and issues most impactful to community oncology